Literature DB >> 15141006

CKII site in Epstein-Barr virus nuclear protein 2 controls binding to hSNF5/Ini1 and is important for growth transformation.

Bogaslaw Kwiatkowski1, Szu Yu Jenny Chen, William H Schubach.   

Abstract

Substitution mutagenesis of EBNA2 shows that its interaction with hSNF5/Ini1 involves two sites (286IPP and DQQ313), and a mutation at a CKII phosphorylation site (SS469) is essential for the interaction. An alanine substitution (SS469AA) prevents binding to EBNA2 and diminishes the growth-promotion potential of EBNA2 in the transcomplementation assay.

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15141006      PMCID： PMC415811          DOI： 10.1128/JVI.78.11.6067-6072.2004

Source DB:  PubMed          Journal:  J Virol        ISSN： 0022-538X            Impact factor:   5.103


  58 in total

1.  A role for SKIP in EBNA2 activation of CBF1-repressed promoters.

Authors:  S Zhou; M Fujimuro; J J Hsieh; L Chen; S D Hayward
Journal:  J Virol       Date:  2000-02       Impact factor: 5.103

2.  A C/EBP beta isoform recruits the SWI/SNF complex to activate myeloid genes.

Authors:  E Kowenz-Leutz; A Leutz
Journal:  Mol Cell       Date:  1999-11       Impact factor: 17.970

3.  Stable transfection of Epstein-Barr virus (EBV) nuclear antigen 2 in lymphoma cells containing the EBV P3HR1 genome induces expression of B-cell activation molecules CD21 and CD23.

Authors:  M Cordier; A Calender; M Billaud; U Zimber; G Rousselet; O Pavlish; J Banchereau; T Tursz; G Bornkamm; G M Lenoir
Journal:  J Virol       Date:  1990-03       Impact factor: 5.103

4.  The level of c-fgr RNA is increased by EBNA-2, an Epstein-Barr virus gene required for B-cell immortalization.

Authors:  J C Knutson
Journal:  J Virol       Date:  1990-06       Impact factor: 5.103

5.  Expression of Epstein-Barr virus transformation-associated genes in tissues of patients with EBV lymphoproliferative disease.

Authors:  L Young; C Alfieri; K Hennessy; H Evans; C O'Hara; K C Anderson; J Ritz; R S Shapiro; A Rickinson; E Kieff
Journal:  N Engl J Med       Date:  1989-10-19       Impact factor: 91.245

6.  Epstein-Barr virus nuclear protein 2 interacts with p300, CBP, and PCAF histone acetyltransferases in activation of the LMP1 promoter.

Authors:  L Wang; S R Grossman; E Kieff
Journal:  Proc Natl Acad Sci U S A       Date:  2000-01-04       Impact factor: 11.205

7.  Promoter-specific targeting of human SWI-SNF complex by Epstein-Barr virus nuclear protein 2.

Authors:  D Y Wu; A Krumm; W H Schubach
Journal:  J Virol       Date:  2000-10       Impact factor: 5.103

8.  Genetic analysis of immortalizing functions of Epstein-Barr virus in human B lymphocytes.

Authors:  W Hammerschmidt; B Sugden
Journal:  Nature       Date:  1989-08-03       Impact factor: 49.962

9.  Epstein-Barr virus nuclear antigen 2 transactivates latent membrane protein LMP1.

Authors:  F Wang; S F Tsang; M G Kurilla; J I Cohen; E Kieff
Journal:  J Virol       Date:  1990-07       Impact factor: 5.103

10.  U2 region of Epstein-Barr virus DNA may encode Epstein-Barr nuclear antigen 2.

Authors:  T Dambaugh; K Hennessy; L Chamnankit; E Kieff
Journal:  Proc Natl Acad Sci U S A       Date:  1984-12       Impact factor: 11.205
View more
  9 in total

1.  Wongabel rhabdovirus accessory protein U3 targets the SWI/SNF chromatin remodeling complex.

Authors:  D Albert Joubert; Julio Rodriguez-Andres; Paul Monaghan; Michelle Cummins; William J McKinstry; Prasad N Paradkar; Gregory W Moseley; Peter J Walker
Journal:  J Virol       Date:  2014-11-12       Impact factor: 5.103

2.  The Epstein-Barr virus EBNA-LP protein preferentially coactivates EBNA2-mediated stimulation of latent membrane proteins expressed from the viral divergent promoter.

Authors:  Rongsheng Peng; Stephanie C Moses; Jie Tan; Elisabeth Kremmer; Paul D Ling
Journal:  J Virol       Date:  2005-04       Impact factor: 5.103

3.  Hyperphosphorylation of EBNA2 by Epstein-Barr virus protein kinase suppresses transactivation of the LMP1 promoter.

Authors:  Wei Yue; Edward Gershburg; Joseph S Pagano
Journal:  J Virol       Date:  2005-05       Impact factor: 5.103

4.  cdc2/cyclin B1-dependent phosphorylation of EBNA2 at Ser243 regulates its function in mitosis.

Authors:  Wei Yue; Julia Shackelford; Joseph S Pagano
Journal:  J Virol       Date:  2006-02       Impact factor: 5.103

5.  Epstein-Barr virus genetic variants are associated with multiple sclerosis.

Authors:  Rosella Mechelli; Caterina Manzari; Claudia Policano; Anita Annese; Ernesto Picardi; Renato Umeton; Arianna Fornasiero; Anna Maria D'Erchia; Maria Chiara Buscarinu; Cristina Agliardi; Viviana Annibali; Barbara Serafini; Barbara Rosicarelli; Silvia Romano; Daniela F Angelini; Vito A G Ricigliano; Fabio Buttari; Luca Battistini; Diego Centonze; Franca R Guerini; Sandra D'Alfonso; Graziano Pesole; Marco Salvetti; Giovanni Ristori
Journal:  Neurology       Date:  2015-03-04       Impact factor: 9.910

6.  C-terminal region of EBNA-2 determines the superior transforming ability of type 1 Epstein-Barr virus by enhanced gene regulation of LMP-1 and CXCR7.

Authors:  Laila Cancian; Rachel Bosshard; Walter Lucchesi; Claudio Elgueta Karstegl; Paul J Farrell
Journal:  PLoS Pathog       Date:  2011-07-28       Impact factor: 6.823

7.  The integrase interactor 1 (INI1) proteins facilitate Tat-mediated human immunodeficiency virus type 1 transcription.

Authors:  Yasuo Ariumi; Fatima Serhan; Priscilla Turelli; Amalio Telenti; Didier Trono
Journal:  Retrovirology       Date:  2006-08-05       Impact factor: 4.602

Review 8.  SWI/SNF chromatin-remodeling factors: multiscale analyses and diverse functions.

Authors:  Ghia Euskirchen; Raymond K Auerbach; Michael Snyder
Journal:  J Biol Chem       Date:  2012-09-05       Impact factor: 5.157

9.  PLK1-dependent phosphorylation restrains EBNA2 activity and lymphomagenesis in EBV-infected mice.

Authors:  Xiang Zhang; Patrick Schuhmachers; André Mourão; Piero Giansanti; Anita Murer; Sybille Thumann; Cornelia Kuklik-Roos; Sophie Beer; Stefanie M Hauck; Wolfgang Hammerschmidt; Ralf Küppers; Bernhard Kuster; Monika Raab; Klaus Strebhardt; Michael Sattler; Christian Münz; Bettina Kempkes
Journal:  EMBO Rep       Date:  2021-10-04       Impact factor: 8.807
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.